After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
COVID-19 could cause surge in virtual trials, says Vertex expertThe COVID-19 crisis is causing a surge in interest in ‘virtual trials’ where the bulk of the data Share XCOVID-19 could cause surge in virtual trials, says Vertex experthttps://pharmaphorum.com/news/covid-19-could-cause-surge-in-virtual-trials-says-vertex-expert/
Shares in Vertex jump on overnight success of CF triple therapyShares in US pharma Vertex were up sharply in premarket trading after its newly-launched cystic fibrosis triple therapy attained blockbuster status Share XShares in Vertex jump on overnight success of CF triple therapyhttps://pharmaphorum.com/news/shares-in-vertex-jump-on-overnight-success-of-cf-triple-therapy/
The 4 biggest pharma market access stories of 2019What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive Share XThe 4 biggest pharma market access stories of 2019https://pharmaphorum.com/views-analysis-market-access/the-4-biggest-pharma-market-access-stories-of-2019/
After four-year wait, patients in England finally get Vertex’s cystic fibrosis drugsNHS England has signed an agreement with US pharma Vertex covering all the company’s licensed cystic fibrosis medicines, Share XAfter four-year wait, patients in England finally get Vertex’s cystic fibrosis drugshttps://pharmaphorum.com/news/breaking-news-nhs-signs-agreement-with-vertex-covering-all-cystic-fibrosis-drugs/
Vertex looks beyond cystic fibrosis with $950m Semma buyVertex Pharma is all-but synonymous with cystic fibrosis (CF) treatment but wants to diversify into new areas, including Share XVertex looks beyond cystic fibrosis with $950m Semma buyhttps://pharmaphorum.com/news/vertex-looks-beyond-cystic-fibrosis-with-950m-semma-buy/
Scotland’s cost regulator rejects Vertex cystic fibrosis drugsScotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of Share XScotland’s cost regulator rejects Vertex cystic fibrosis drugshttps://pharmaphorum.com/news/scotlands-cost-regulator-rejects-vertex-cystic-fibrosis-drugs/
Minister says using generic CF drug is an option in Orkambi rowVertex is coming under increased pressure to sign a deal with the NHS covering its Orkambi cystic fibrosis Share XMinister says using generic CF drug is an option in Orkambi rowhttps://pharmaphorum.com/news/minister-says-using-generic-cf-drug-is-an-option-in-orkambi-row/
Orkambi parents start ‘buyers club’ to import generic version of CF drugA group of parents in the UK have taken matters into their own hands in an effort to Share XOrkambi parents start ‘buyers club’ to import generic version of CF drughttps://pharmaphorum.com/news/orkambi-parents-start-buyers-club-to-import-generic-version-of-cf-drug/
